Q-omics provides the consensus-scored ZNF334 profile across patient tissues and cancer cell-line models. ZNF334 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ZNF334 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, ZNF334 RNA expression shows 18,455 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, COAD, and THYM as cancer lineages where ZNF334 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF334 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF334 survival associations across molecular data types. ZNF334 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF334 RNA expression–survival associations across cancer types. High ZNF334 expression shows unfavorable associations in STAD, LGG, UCEC and HNSC, but favorable associations in KIRP and UCS. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify KIRP as the clearest survival context for ZNF334 RNA expression.
This table summarizes ZNF334 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF334. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF334 shows lower tumor expression in COAD, UCEC, BRCA, LUAD, THCA and KICH. The COAD box plot shows higher ZNF334 RNA expression in normal versus tumor tissue (log2 FC = −0.586, t-test p < 0.001).
This table shows molecular features associated with ZNF334 in patient tissues and cancer cell lines. In patient samples, ZNF334 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF334 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
